

Special Issue

Precision Medicine in Urologic Oncology: Diagnosis, Treatment and Prognosis

Message from the Guest Editor

Malignant tumors emerging from the urinary tract make up a significant part of all human neoplastic diseases, with prostate cancer being the second most commonly diagnosed malignancy among men worldwide. Because of their aggressive clinical course and substantial burden for both healthcare systems and for individual patients, every effort should be undertaken to develop more precise diagnostic methods and more effective therapeutic modalities. In this Special Issue of *JPM*, we present a series of high-quality original articles and meta-analyses concerning various urologic malignancies, illustrating the current developments in both diagnosis and treatment.

Guest Editor

Dr. Wojciech Krajewski
Department of Urology and Oncologic Urology, Wrocław Medical University, 50-556 Wrocław, Poland

Deadline for manuscript submissions

closed (15 July 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/92211

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).